Payment overview · 2025
General Payments
$535.18
21 reported records · 14 companies
Healthcare provider profile · identity verified
Ryan E Tyler, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WATERTOWN, NY · NPI 1336198639
Verified facts
What the public records show
CMS Open Payments records show Ryan E Tyler, M.D. received $535.18 in general payments during 2025 across 21 reported records.
Madrigal Pharmaceuticals accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Otezla.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $95.54 | 17.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $89.49 | 16.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $86.10 | 16.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.23 | 7.5% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $39.13 | 7.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $38.97 | 7.3% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $25.34 | 4.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.97 | 4.7% | 1 | 2025 |
| Fisher & Paykel Healthcare Inc | Unresolved — no canonical attribution shown | $20.40 | 3.8% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.95 | 3.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.96 | 2.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.74 | 2.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.62 | 2.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.74 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $535.18 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $95.54 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $76.01 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.22 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.22 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.23 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $40.23 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $39.13 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $38.97 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $25.34 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| FISHER & PAYKEL HEALTHCARE Normalized: fisher paykel healthcare |
Device | Fisher & Paykel Healthcare Inc | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 230 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
230 | 57 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
143 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
230 | 57 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 628 | 145 |
| Atorvastatin Calcium | Atorvastatin Calcium | 604 | 157 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 578 | 141 |
| Omeprazole | Omeprazole | 442 | 115 |
| Metformin Hcl Er | Metformin Hcl | 357 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 296 | 78 |
| Lisinopril | Lisinopril | 273 | 70 |
| Gabapentin | Gabapentin | 262 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 261 | 69 |
| Telmisartan | Telmisartan | 251 | 73 |
| Eliquis | Apixaban | 230 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 210 | 90 |
| Carvedilol | Carvedilol | 187 | 51 |
| Chlorthalidone | Chlorthalidone | 178 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 176 | 63 |
| Furosemide | Furosemide | 174 | 45 |
| Torsemide | Torsemide | 168 | 49 |
| Irbesartan | Irbesartan | 161 | 38 |
| Ozempic | Semaglutide | 157 | 44 |
| Potassium Chloride | Potassium Chloride | 154 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 42 |
| Simvastatin | Simvastatin | 144 | 33 |
| Jardiance | Empagliflozin | 143 | 36 |
| Montelukast Sodium | Montelukast Sodium | 140 | 33 |
| Trazodone Hcl | Trazodone Hcl | 139 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 26 |
| Ezetimibe | Ezetimibe | 116 | 27 |
| Allopurinol | Allopurinol | 113 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 26 |
| Glimepiride | Glimepiride | 110 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 28 |
| Spironolactone | Spironolactone | 106 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 105 | 22 |
| Atenolol | Atenolol | 103 | 21 |
| Metformin Hcl | Metformin Hcl | 103 | 25 |
| Celecoxib | Celecoxib | 96 | 29 |
| Losartan Potassium | Losartan Potassium | 90 | 23 |
| Tramadol Hcl | Tramadol Hcl | 90 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 89 | 22 |
| Januvia | Sitagliptin Phosphate | 88 | 20 |
| Baclofen | Baclofen | 87 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 20 |
| Famotidine | Famotidine | 84 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 24 |
| Prednisone | Prednisone | 73 | 35 |
| Sertraline Hcl | Sertraline Hcl | 73 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 72 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 18 |
| Alendronate Sodium | Alendronate Sodium | 66 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 13 |
| Xarelto | Rivaroxaban | 65 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 64 | suppressed |
| Lansoprazole | Lansoprazole | 61 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 60 | 17 |
| Trulicity | Dulaglutide | 58 | 18 |
| Warfarin Sodium | Warfarin Sodium | 58 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 16 |
| Divalproex Sodium | Divalproex Sodium | 55 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Pregabalin | Pregabalin | 54 | 19 |
| Sucralfate | Sucralfate | 53 | 17 |
| Alprazolam | Alprazolam | 50 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 16 |
| Valacyclovir | Valacyclovir Hcl | 48 | 18 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 47 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 46 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | suppressed |
| Fluconazole | Fluconazole | 45 | 17 |
| Ramipril | Ramipril | 43 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 13 |
| Nystatin | Nystatin | 41 | 20 |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Nitroglycerin | Nitroglycerin | 39 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | 11 |
| Bupropion Xl | Bupropion Hcl | 37 | 12 |
| Finasteride | Finasteride | 37 | 11 |
| Primidone | Primidone | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | 11 |
| Olanzapine | Olanzapine | 36 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 34 | suppressed |
| Lorazepam | Lorazepam | 32 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | suppressed |
| Meloxicam | Meloxicam | 31 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 25 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 28 | suppressed |
| Febuxostat | Febuxostat | 27 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 25 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Calcitriol | Calcitriol | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Rytary | Carbidopa/Levodopa | 24 | suppressed |
| Dexamethasone | Dexamethasone | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Phenobarbital | Phenobarbital | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 15 |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 15 |
| Digoxin | Digoxin | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Buprenorphine | Buprenorphine | 16 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Rybelsus | Semaglutide | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Ramelteon | Ramelteon | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Ursodiol | Ursodiol | 14 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 13 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Humira(Cf) Pen | Adalimumab | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $535.18 · 21 records | Madrigal Pharmaceuticals | AIRSUPRA, AREXVY, CAPLYTA, ELIQUIS, EVENITY, FISHER & PAYKEL HEALTHCARE, FREESTYLE LIBRE 3, INSPIRE, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, REPATHA, REZDIFFRA, SHINGRIX, TZIELD, VOQUEZNA, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error